Compare Robinhood Markets, Inc. (HOOD) vs Heron Therapeutics Inc (HRTX) Price & Performance

Robinhood (HOOD) trades at $108.95, down 0.51% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $4.47B and net income of $1.88B, though valuation ratios like P/E of 47.35 are elevated. Recent news highlights expansion into 24/7 stock trading and AI-driven features, signaling growth initiatives.

Outlook remains positive with a consensus price target of $137.53, offering ~26% upside, but risks include high valuation sensitivity and competitive pressures in the brokerage sector. Earnings beat in two of the last three quarters supports growth trajectory, though investors should monitor execution on new product launches and regulatory developments.

HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.

The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.